Abiopharma

🔍 Donnally James O (Director)

Company: Innventure, Inc. (INV)

Report Date: 2026-04-17

Detailed Transactions and Holdings:

• Acquired 80,848 shares of Common Stock (Direct)
  Date: 2026-04-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,607,619.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 27,849 shares of Common Stock (Direct)
  Date: 2026-04-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,708,121.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4

Footnotes:

• F1: This transaction is being reported late due to an administrative error.
• F2: Received in connection with the achievement of a milestone pursuant to the Business Combination Agreement (as amended and supplemented or otherwise modified), dated as of October 24, 2023, by and among Innventure, Inc. (the "Issuer") (f/k/a Learn SPAC HoldCo, Inc.), Learn CW Investment Corporation, Innventure LLC, a wholly-owned subsidiary of the Issuer, LCW Merger Sub, Inc., and Innventure Merger Sub, LLC.
• F3: Represents shares of Common Stock held by the James O. Donnally Revocable Trust, for which the Reporting Person has voting and investment power over the shares of Common Stock held by that trust.
• F4: Represents shares of Common Stock held directly by the Glockner Family Venture Fund (the "Glockner Fund"). The Reporting Person is a 25% owner of the Glockner Fund and is a 25% owner and the Managing Member of Bellringer Consulting Group, LLC ("Bellringer"), the general partner of the Glockner Fund. The Reporting Person has no authority over the Glockner Fund's decision-making with respect to equity or debt investments in the Issuer and disclaims beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any. The inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Exchange Act of 1934.